D-Cycloserine

Phase 2Small molecule

MMassachusetts General Hospital

D-Cycloserine is one of 57 small molecule programs targeting Suicide. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SuicideRecruiting

DepressionActive, not recruiting

PTSD - Post Traumatic Stress DisorderNot yet recruiting

Magnetic Resonance ImagingCompleted

Emotional ProcessingCompleted

Borderline Personality Disorder (BPD)Recruiting

Major DepressionNot yet recruiting

SuicidePhase 2

Recruiting

DepressionPhase 2

Active, not recruiting

PTSD - Post Traumatic Stress DisorderPhase 2

Not yet recruiting

Magnetic Resonance ImagingPreclinical

Completed

Emotional ProcessingPreclinical

Completed

Borderline Personality Disorder (BPD)Preclinical

Recruiting

Major DepressionPreclinical

Not yet recruiting

Competition

Competitive Landscape

42 competitors in Depression

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Approved

13 2

Ketalar

AAultman Health Foundation

Approved

23 3

Brintellix

Takeda

Approved

7 4

Zoloft

VViatris Specialty LLC

Approved

20 5

Vraylar

AbbVie

Approved

4 6

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

14 7

Wellbutrin

GGlaxo Dba Glaxosmithkline

Approved

10 8

Trexall

Jazz Pharmaceuticals

Approved

1 9

Estrace

Novo Nordisk

Approved

1 10

Spravato

WWim Janssens

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Depression

NCT07868627

Q4 2027

PreclinicalRecruiting

Borderline Personality Disorder (BPD)

NCT07460947

Q4 2028

ApprovedRecruiting

Nicotine Dependence

NCT07145866

Q1 2029

Phase 2Not yet recruiting

PTSD - Post Traumatic Stress Disorder

NCT07777380

Phase 2Not yet recruiting

PTSD - Post Traumatic Stress Disorder

NCT07773935

Clinical

Trials by Indication[1]

Cycloserine23 trials

Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo

Completed·UUniversity of California, Los Angeles·N/A·NCT02582515·20 enrolled

D-Cycloserine to Enhance Extinction to Alcohol Cues

Completed·UUniversity of Georgia·N/A·NCT01362309·37 enrolled

D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT)

Active, not recruiting·TThe Alfred·Phase 2·NCT05591677·180 enrolled

Show 20 more trials

The Use of D-Cycloserine to Augment CBT for Pediatric OCD

Unknown status·UUniversity of California, Los Angeles·Phase 2·NCT01687140·26 enrolled

D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD

Completed·NNew York State Psychiatric Institute·N/A·NCT01172873·16 enrolled

D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder

Completed·MMassachusetts General Hospital·Phase 1·NCT00842309·68 enrolled

D-Cycloserine Enhancement of Exposure in Social Phobia

Completed·MMassachusetts General Hospital·Phase 4·NCT00633984·169 enrolled

D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

Completed·NNYU Langone Health·Phase 4·NCT01981759·58 enrolled

The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly

Completed·HHartford Hospital·Phase 2·NCT01361633·51 enrolled

Cognitive Remediation With D-Cycloserine

Completed·MMassachusetts General Hospital·Phase 3·NCT01399866·150 enrolled

RCT of CBT Combined With D-Cycloserine for Treating PTSD

Unknown status·UUniversité de Montréal·Phase 2/3·NCT00452231·20 enrolled

Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine

Completed·RRose Research Center, LLC·Phase 2·NCT05994703·25 enrolled

2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD

Completed·MMassachusetts General Hospital·N/A·NCT01404208·206 enrolled

Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine

Completed·MMclean Hospital·Phase 1·NCT02304432·2 enrolled

Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers

Withdrawn·NNew York State Psychiatric Institute·Phase 2·NCT01907594

D-cycloserine and Treatment of Feeding Disorders

Completed·EEmory University·Phase 1/2·NCT01923896·16 enrolled

A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD

Completed·UUS Department of Veterans Affairs·N/A·NCT00371176·26 enrolled

D-Cycloserine Facilitation of Cocaine - Cue Extinction

Completed·MMedical University of South Carolina·Phase 2·NCT00759473·79 enrolled

D-Cycloserine as an Adjunct to Internet-CBT for OCD

Completed·CChristian Rück·Phase 4·NCT01649895·128 enrolled

D-Cycloserine+iTBS PK Study

Completed·UUniversity of Calgary·Phase 1·NCT05731323·12 enrolled

Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD

Withdrawn·—·Phase 2/3·NCT03216356

D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia

Completed·UUnknown Sponsor·Phase 3·NCT01102803·40 enrolled

Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia

Completed·—·Phase 3·NCT00515879·169 enrolled

Schizophrenia7 trials

Glycine and D-Cycloserine in Schizophrenia

Withdrawn·MMassachusetts General Hospital·Phase 3·NCT00000372

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

Completed·MMassachusetts General Hospital·N/A·NCT00963924·54 enrolled

Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia

Completed·MMassachusetts General Hospital·Phase 4·NCT00742079·21 enrolled

Show 4 more trials

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

Completed·UUniversity of Maryland, Baltimore·Phase 2/3·NCT00222235·240 enrolled

Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia

Completed·MMassachusetts General Hospital·Phase 4·NCT00455702·38 enrolled

Once Weekly D-cycloserine for Schizophrenia

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT00964041

Trial of D-Cycloserine in Schizophrenia

Completed·MMassachusetts General Hospital·Phase 3·NCT00000371·60 enrolled

Obsessive-Compulsive Disorder6 trials

Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients?

Completed·HHaukeland University Hospital·Phase 4·NCT02656342·163 enrolled

D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder

Withdrawn·UUniversity of Florida·Phase 2·NCT00257361

D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)

Completed·UUniversity of South Florida·Phase 3·NCT01411774·142 enrolled

Show 3 more trials

D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder

Completed·UUniversity of South Florida·Phase 2·NCT00864123·30 enrolled

iTBS-DCS in Obsessive Compulsive Disorder

Unknown status·UUniversity of Calgary·Phase 2·NCT05177601·81 enrolled

A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder

Completed·MMassachusetts General Hospital·N/A·NCT00126282·50 enrolled

Post-Traumatic Stress Disorder, PTSD3 trials

D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents

Completed·TTulane University School of Medicine·Phase 2·NCT01157429·24 enrolled

Effect of D-cycloserine on Treatment of Posttraumatic Stress Disorder (PTSD) in Youth

Completed·TTulane University School of Medicine·Phase 2·NCT01157416·33 enrolled

Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)

Completed·WWeill Medical College of Cornell University·N/A·NCT00632632·25 enrolled

Panic Disorder3 trials

Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder

Completed·HHartford Hospital·N/A·NCT00131339·40 enrolled

D-cycloserine Augmented CBT for Panic Disorder

Terminated·UUniversity of Oxford·Phase 3·NCT01680107·33 enrolled

Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder

Completed·—·Phase 2·NCT00790868·180 enrolled

43 more indications

Virtual Reality2 trials

Virtual Reality and D-Cycloserine in Combat Related Psycological Trauma in Burn Service Members

Withdrawn·UUnited States Army Institute of Surgical Research·N/A·NCT00855153

D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

Completed·EEmory University·Phase 2/3·NCT00356278·156 enrolled

Low back pain2 trials

D-cycloserine in the Management of Chronic Low Back Pain

Completed·—·Phase 2·NCT00125528·41 enrolled

D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain

Terminated·NNorthwestern University·Phase 2·NCT03535688·203 enrolled

Memory2 trials

Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments

Completed·RRoger K. Pitman, MD·Phase 4·NCT01490697·34 enrolled

Glutamate, Learning, and Working Memory

Completed·UUniversity of California, Los Angeles·Phase 1·NCT02769936·110 enrolled

Smoking Cessation2 trials

D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation (DCSSmoking)

Withdrawn·—·Phase 2·NCT00827281

Multimodal Cue Exposure Therapy for Smoking Cessation

Withdrawn·—·Phase 2·NCT04035603

Autism2 trials

Safety and Effectiveness of D-Cycloserine in Children With Autism

Completed·IIndiana University·Phase 3·NCT00198120·80 enrolled

Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism

Completed·IIndiana University·Phase 3·NCT00198107·81 enrolled

Major Depressive Disorder2 trials

Adjunctive D-Cycloserine in Major Depressive Disorder

Completed·UUniversity of Calgary·Phase 2·NCT03937596·50 enrolled

D-cycloserine for Major Depressive Disorder

Completed·HHerzog Hospital·Phase 2·NCT00408031·26 enrolled

PTSD - Post Traumatic Stress Disorder2 trials

One-day rTMS + D-cycloserine to Treat PTSD in Military Personnel and Veterans

Not yet recruiting·FFidel Vila-Rodriguez, MD, PhD, FRCPC, DFAPA·Phase 2·NCT07777380·50 enrolled

One-day rTMS + D-cycloserine to Treat PTSD in First Responders

Not yet recruiting·FFidel Vila-Rodriguez, MD, PhD, FRCPC, DFAPA·Phase 2·NCT07773935·50 enrolled

Emotional Processing1 trial

The Effect of D-cycloserine on Emotional Processing

Completed·UUniversity of Oxford·N/A·NCT03961464·40 enrolled

Bipolar Depression1 trial

NMDA Antagonists in Bipolar Depression

Completed·NNew York State Psychiatric Institute·Phase 4·NCT01833897·8 enrolled

Fibromyalgia1 trial

iTBS-DCS in Fibromyalgia

Terminated·UUniversity of Calgary·Phase 2·NCT05395494·47 enrolled

Spinal Cord Injury1 trial

Lower Limb Function After Spinal Cord Injury

Completed·SShirley Ryan AbilityLab·Phase 4·NCT02635893·257 enrolled

Substance Use1 trial

Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use

Terminated·—·Phase 2·NCT00430573·15 enrolled

Smoking Reduction1 trial

Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine

Completed·UUniversity of Texas at Austin·Phase 1·NCT01944423·53 enrolled

AIN1 trial

Understanding the Importance of Plasticity in the Brain Mechanisms of Dyspnoea Perception

Unknown status·UUniversity of Oxford·Phase 1·NCT01985750·90 enrolled

Magnetic Resonance Imaging1 trial

Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics

Completed·HHartford Hospital·N/A·NCT01450306·20 enrolled

Brain Injury1 trial

The Effect of Single Dose D-Cycloserine on Cognitive Outcome in Moderate Traumatic Brain Injury (TBI) Patients

Unknown status·HHadassah Medical Organization·Phase 2·NCT01343862·100 enrolled

Fear1 trial

Exploring Learning and Unlearning of Fear

Withdrawn·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT01512316

Antibiotic1 trial

Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia

Completed·NNational Institute of Mental Health (NIMH)·Phase 2·NCT00128401·48 enrolled

Suicide1 trial

iTBS+D-Cycloserine for Youth Suicide

Recruiting·UUniversity of Calgary·Phase 2·NCT06121284·54 enrolled

Cognitive Function1 trial

Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression

Completed·—·N/A·NCT03062150·232 enrolled

Autism Spectrum Disorder1 trial

D-Cycloserine and Social Skills Training in Autism Spectrum Disorders

Completed·IIndiana University·Phase 3·NCT01086475·68 enrolled

Transcranial Direct Current Stimulation1 trial

Transcranial Direct Current Stimulation (tDCS) Augmentation by D-Cycloserine as a Treatment for Depression

Completed·TThe University of New South Wales·Phase 2·NCT00869765·5 enrolled

Pain1 trial

Pain, Learning, and Nocebo

Completed·LLeiden University Medical Center·N/A·NCT04762836·53 enrolled

Neuropathic Pain1 trial

D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain

Terminated·NNorthwestern University·Phase 3·NCT00301080·7 enrolled

ESS1 trial

The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes

Unknown status·—·Phase 2/3·NCT00926900·80 enrolled

Agoraphobia1 trial

Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia

Completed·—·Phase 2·NCT01928823·73 enrolled

Specific Phobia1 trial

fMRI Study Examining Effects of D-cycloserine in Specific Phobia

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT00591825·54 enrolled

Treatment Resistant Depression1 trial

D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression

Unknown status·SSheba Medical Center·Phase 4·NCT02772211·60 enrolled

Children1 trial

Augmentation of Cognitive Training in Children With TBI With D-Cyloserine

Unknown status·UUniversity of California, Los Angeles·Phase 1·NCT02312635·30 enrolled

Humans1 trial

NMDA Receptors in Motor Learning in Humans

Completed·EEmory University·Phase 2·NCT02082912·14 enrolled

Chronic Pelvic Pain Syndrome1 trial

Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain

Terminated·NNorthwestern University·Phase 4·NCT02385266·24 enrolled

Cocaine Dependence1 trial

Improving Learning-based Treatment of Cocaine Dependence With Medication

Completed·JJohns Hopkins University·Phase 2·NCT01526538·52 enrolled

Tic Disorder1 trial

D-cycloserine Augmented Treatment for Youth With Tic Disorders

Withdrawn·JJohns Hopkins University·Phase 1·NCT04357951

Veteran1 trial

Veteran Stress and Learning Study

Completed·VVA Office of Research and Development·Phase 4·NCT00674570·111 enrolled

Cocaine-dependent1 trial

D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals

Completed·MMedical University of South Carolina·Phase 2·NCT00780442·27 enrolled

Social Anxiety Disorder1 trial

Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder

Completed·UUniversity of Texas at Austin·Phase 1·NCT02066792·152 enrolled

Major Depression1 trial

Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder

Recruiting·MMclean Hospital·Preclinical·NCT07593222·100 enrolled

Phobia1 trial

D-Cycloserine as Enhancer of One-Session Treatment for Phobia of Heights in Adults

Terminated·CCAMC Health System·Phase 2·NCT01037101·4 enrolled

Depression1 trial

Novel and Conventional Interventions for Cognitive and Emotional Flexibility in Patient Trauma

Active, not recruiting·MMclean Hospital·Phase 2·NCT07868627·75 enrolled

Nicotine Dependence1 trial

Evaluation of Varenicline and Accelerated TMS for Reduction of Nicotine Use

Recruiting·MMassachusetts General Hospital·Approved·NCT07145866·30 enrolled

Gulf War Illness1 trial

D-cycloserine: A Novel Treatment for Gulf War Illness

Completed·BBoston University Charles River Campus·Phase 2·NCT02983734·22 enrolled

Borderline Personality Disorder (BPD)1 trial

A Pilot Trial of One Day Accelerated Intermittent Theta-burst Stimulation Plus D-cycloserine in Suicidal Patients With Borderline Personality Disorder (ONE-D BPD)

Recruiting·MMclean Hospital·Preclinical·NCT07460947·20 enrolled

Unspecified1 trial

AIH for Spinal Cord Repair

Terminated·VVA Office of Research and Development·Phase 1·NCT03780829·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 92 trial records for D-Cycloserine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D-Cycloserine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D-Cycloserine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMassachusetts General Hospital

D-Cycloserine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2028

Q1 2029

Trials by Indication[1]

Cycloserine23 trials

Schizophrenia7 trials

Obsessive-Compulsive Disorder6 trials

Post-Traumatic Stress Disorder, PTSD3 trials

Panic Disorder3 trials

Virtual Reality2 trials

Low back pain2 trials

Memory2 trials

Smoking Cessation2 trials

Autism2 trials

Major Depressive Disorder2 trials

PTSD - Post Traumatic Stress Disorder2 trials

Emotional Processing1 trial

Bipolar Depression1 trial

Fibromyalgia1 trial

Spinal Cord Injury1 trial

Substance Use1 trial

Smoking Reduction1 trial

AIN1 trial

Magnetic Resonance Imaging1 trial

Brain Injury1 trial

Fear1 trial

Antibiotic1 trial

Suicide1 trial

Cognitive Function1 trial

Autism Spectrum Disorder1 trial

Transcranial Direct Current Stimulation1 trial

Pain1 trial

Neuropathic Pain1 trial

ESS1 trial

Agoraphobia1 trial

Specific Phobia1 trial

Treatment Resistant Depression1 trial

Children1 trial

Humans1 trial

Chronic Pelvic Pain Syndrome1 trial

Cocaine Dependence1 trial

Tic Disorder1 trial

Veteran1 trial

Cocaine-dependent1 trial

Social Anxiety Disorder1 trial

Major Depression1 trial

Phobia1 trial

Depression1 trial

Nicotine Dependence1 trial

Gulf War Illness1 trial

Borderline Personality Disorder (BPD)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News